Viatris Inc. reported total revenues of $14.30 billion for the year ended December 31, 2025, a decrease of $439.4 million, or 3%, compared to $14.74 billion in 2024. The decline was attributed to the impact of divestitures completed during 2024 and the supply disruptions and FDA-issued warning letter and import alert related to its oral finished dose manufacturing facility in Indore, India, referred to as the Indore Impact. Net loss for 2025 was $3.51 billion, or $3.00 per diluted share, compared to a net loss of $634.2 million, or $0.53 per diluted share, in the previous year.
The company highlighted several strategic accomplishments in 2025, including strong commercial execution despite revenue headwinds, and advancements in its innovative pipeline with five positive Phase 3 data readouts. Viatris also returned over $1 billion of capital to shareholders through share repurchases and dividends. The company completed its initial remediation activities at the Indore facility and is in regular communication with the FDA. Furthermore, Viatris acquired Aculys Pharma, expanding its portfolio of innovative medicines in Japan.
Significant operational developments included the launch of Iron Sucrose Injection, USP, in the U.S. and the first approval for Inpefa® (sotagliflozin) in the United Arab Emirates. The company also initiated an enterprise-wide strategic review (EWSR) in 2025, aimed at building a more focused and efficient organization for sustained growth. As a result of the EWSR, Viatris expects a global workforce reduction of up to approximately 10% and anticipates total pre-tax charges ranging between $700 million and $850 million, with potential savings between $600 million and $700 million once fully implemented.
Looking ahead, Viatris identified three strategic imperatives: driving the base business, fueling the innovative portfolio, and modernizing for sustainable growth. The company expects to focus on successful product launches, supply chain continuity, and evolving its generics portfolio towards higher-margin products. Viatris also aims to advance its pipeline of late-stage and in-market growth assets and strengthen its technology, data, and talent capabilities. However, in mid-February 2026, a fire occurred in a service area at the Company's oral solid dose manufacturing facility in Nashik, India, temporarily suspending manufacturing. The Company expects to resume operations beginning in April 2026.
About Viatris Inc
Viatris is a global healthcare company providing high-quality medicines across multiple therapeutic areas, including generics, branded, complex, and innovative drugs. Serving over 1 billion patients annually in more than 165 countries, it leverages a diversified portfolio, extensive supply chain, and scientific expertise to improve access and address unmet medical needs worldwide. Its business model emphasizes sustainability, strategic partnerships, and expanding innovative product offerings.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.